| 摘要 |
Disclosed is a pharmaceutical composition comprising 40 to 500 mg of an antibody or an antigen-binding fragment thereof which specifically binds human proprotein convertase subtilisin/kexin type 9 (hPCSK9) together with a pharmaceutically acceptable excipient or carrier for use in the treatment of a disease or condition in which PCSK9 expression or activity causes an impact, wherein the pharmaceutical composition is formulated according to a dosing regime providing the antibody or antigen-binding fragment thereof about every two or four weeks, and wherein the antibody or antigen-binding fragment thereof comprises the CDRs or the heavy/light chain sequences as defined in the specification. |
